Bristol-Myers Squibb Quarterly Income Statement
NYSE: BMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bristol-Myers Squibb revenue and earnings
In the quarter ended Jun 30, 2026, Bristol-Myers Squibb generated $12.97 billion in revenue, up 5.7% from the same quarter a year earlier. Net income was $3.32 billion (+153.2% year over year), for a net margin of 25.6% versus a median of 18.0% in the prior 5 quarters. Gross margin was 71.3% (down from 72.5%).
Diluted earnings per share came in at $1.62, up from $0.64.
Summary generated from market data by MetaCap's automated system. Methodology
Bristol-Myers Squibb income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.97B | 11.49B | 12.50B | 12.22B | 12.27B | 11.20B | 12.34B | 11.89B | 12.20B | 11.87B | 11.48B | 10.97B |
| Revenue growth (YoY) | +5.74% | +2.57% | +1.30% | +2.77% | +0.56% | -5.60% | +7.54% | +8.44% | +8.69% | +4.66% | +0.62% | -2.25% |
| Cost of Revenue | 3.73B | 3.42B | 4.10B | 3.44B | 3.37B | 3.03B | 4.81B | 2.96B | 3.27B | 2.93B | 2.75B | 2.51B |
| Gross Profit | 9.25B | 8.07B | 8.40B | 8.79B | 8.90B | 8.17B | 7.53B | 8.94B | 8.93B | 8.93B | 8.73B | 8.46B |
| Research & Development | 2.96B | 2.65B | 2.59B | 2.53B | 2.58B | 2.26B | 3.19B | 2.37B | 2.90B | 2.69B | 2.48B | 2.24B |
| Selling, General & Admin | 1.83B | 1.62B | 2.18B | 1.79B | 1.71B | 1.58B | 2.14B | 1.98B | 1.93B | 2.37B | 2.07B | 2.00B |
| Interest Expense | 407.00M | 411.00M | 432.00M | 480.00M | 485.00M | 494.00M | 496.00M | 505.00M | 521.00M | 425.00M | 316.00M | 280.00M |
| Other Income (Expense) | 61.00M | -32.00M | 51.00M | 108.00M | -494.00M | -339.00M | -305.00M | -234.00M | -273.00M | -81.00M | 371.00M | 258.00M |
| Pretax Income | 4.09B | 3.24B | 1.47B | 3.11B | 1.77B | 2.97B | 175.00M | 1.68B | 1.29B | -11.52B | 1.67B | 2.14B |
| Income Tax | 770.00M | 561.00M | 384.00M | 919.00M | 460.00M | 509.00M | 99.00M | 461.00M | -398.00M | 392.00M | -88.00M | 203.00M |
| Net Income | 3.32B | 2.68B | 1.09B | 2.20B | 1.31B | 2.46B | 72.00M | 1.21B | 1.68B | -11.91B | 1.76B | 1.93B |
| Net Income growth (YoY) | +153.21% | +9.00% | +1409.72% | +81.75% | -22.02% | — | -95.91% | -37.19% | -18.96% | -626.57% | -12.86% | +20.05% |
| EPS (Basic) | 1.62 | 1.31 | 0.54 | 1.08 | 0.64 | 1.21 | 0.05 | 0.60 | 0.83 | -5.89 | 0.87 | 0.94 |
| EPS (Diluted) | 1.62 | 1.31 | 0.54 | 1.08 | 0.64 | 1.20 | 0.05 | 0.60 | 0.83 | -5.89 | 0.87 | 0.93 |
| Shares Outstanding (Basic) | 2.04B | 2.04B | — | 2.04B | 2.04B | 2.03B | — | 2.03B | 2.03B | 2.02B | — | 2.06B |
| Shares Outstanding (Diluted) | 2.05B | 2.05B | — | 2.04B | 2.04B | 2.04B | — | 2.03B | 2.03B | 2.02B | — | 2.06B |
| Gross Margin | 71.28% | 70.22% | 67.23% | 71.89% | 72.52% | 72.92% | 61.01% | 75.13% | 73.22% | 75.29% | 76.08% | 77.15% |
| Net Margin | 25.57% | 23.30% | 8.69% | 18.01% | 10.68% | 21.93% | 58.00% | 10.18% | 13.77% | -100.39% | 15.35% | 17.58% |
This table shows 12 quarterly periods of Bristol-Myers Squibb's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BMY's reporting calendar. What is a income statement?